CYTR..$2.07..in AH. I am of the opinion that the data is going to be positive and that is why I took a stab at it in my beginner portfolio. I had the opportunity to sell today and decided against it. I don't just take dumb risks and hope to get lucky. This was a well thought out and calculated risk & either way I am ok if I lose a few thousand dollars. I hope that the data is strong but I have been known to be wrong on occasion when holding thru an event. Most of the time I am on the right side of an event. What seems obvious to me may end up not being so obvious and being wrong. I think Aldoxorubicin WILL show stat sign comparison vs DOX with PFS around 5-6 months.
Why I think positive data: Recent Large Insider buys (within weeks), coordinated conferences (press release & Oppenheimer) on the same day, a lot of promo (Mission IR) over past month and conferences.
CYTR Patterson Scott Bradford CYTR Common Stock, $0.01 par value per share 11/29/2013 P 165700 A $2.4813 4793305 D CYTR Common Stock, $0.01 par value per share 12/2/2013 P 77148 A $2.391 4870453 D CYTR Common Stock, $0.01 par value per share 12/3/2013 P 42131 A $2.3476 4912584
CYTR..CytRx rallies after conference presentation CytRx (CYTR) trades 6% higher in premarket action.Investors seem pleased with Tuesday's presentation at the LD MICRO Main Event Conference in L.A. The company discussed aldoxorubicin, reviewed some data from on-going Phase 2 trials, and talked a bit about the upcoming Phase 3 study (Q1 2014 is planned start).CYTR also presented a timeline, outlining "numerous upcoming catalysts." http://wsw.com/webcast/ldmicro5/CYTR/
News 
Market Data 
Discover 
AI
